Patents by Inventor Prem Sagar Akasapu
Prem Sagar Akasapu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230355604Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: ApplicationFiled: June 28, 2023Publication date: November 9, 2023Applicant: Vyluma Inc.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan Ali Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Patent number: 11779535Abstract: Pre-filled syringes, pharmaceutical compositions, and kits and methods relating to same allow for emergency administration of one or more drugs from prefilled glass syringes to a patient via a needleless connector. In preferred embodiments, the prefilled glass syringe has a drug volume of at least 5 mL, has a Luer-lock, and has a syringe tip with an internal channel that has a diameter of about 1.7 mm. Such syringes advantageously allow storage of emergency drugs without leaching of plastic materials and degradation, and substantially improve the safety profile where the syringe is attached to an IV line via a needleless connector.Type: GrantFiled: June 23, 2020Date of Patent: October 10, 2023Assignee: NEVAKAR INJECTABLES INC.Inventors: Kumaresh Soppimath, Prem Sagar Akasapu
-
Publication number: 20230181525Abstract: The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.Type: ApplicationFiled: December 9, 2022Publication date: June 15, 2023Inventors: Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Publication number: 20230181526Abstract: The invention described here provides methods of efficiently treating vitamin C deficiency-related diseases and other conditions comprising the administration of pharmaceutical compositions comprising ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The methods comprise administration of such compositions in ready-to-use (RTU) form, provided in single unit dose packaging, wherein the compositions are stable when stored at 20° C. to 25° C. ± 2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use.Type: ApplicationFiled: December 9, 2022Publication date: June 15, 2023Inventors: Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Patent number: 11517522Abstract: The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.Type: GrantFiled: January 13, 2021Date of Patent: December 6, 2022Assignee: SOMERSET THERAPEUTICS LLCInventors: Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Patent number: 11464769Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: July 20, 2020Date of Patent: October 11, 2022Assignee: VYLUMA INC.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Patent number: 11433084Abstract: The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. The invention particularly relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization or autoclaving of an aqueous slurry of methylprednisolone acetate in the presence of a specified quantity of polysorbate. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.Type: GrantFiled: February 14, 2020Date of Patent: September 6, 2022Assignee: Somerset Therapeutics LLCInventors: Rahul Kalhapure, Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Patent number: 11400068Abstract: The present invention relates to liquid formulations of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulations are devoid of tromethamine. In particular, the invention provides a stable ready-to-use liquid formulation of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulation is devoid of tromethamine. The formulations prepared by using the current invention exhibit good physical and chemical stability.Type: GrantFiled: June 14, 2021Date of Patent: August 2, 2022Assignee: SOMERSET THERAPEUTICS LLCInventors: Prem Sagar Akasapu, Rahul Kalhapure, Mandar V. Shah, Shambhavi Borde, Veerappan Subramanian, Ilango Subramanian
-
Patent number: 11382863Abstract: The present invention relates to a process for preparation of an insoluble corticosteroid and a soluble corticosteroid composition by moist heat sterilization and homogenization. In particular, the invention relates to a process for the preparation of a sterilized suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises sterilizing a slurry of the betamethasone acetate by moist heat sterilization or autoclaving in about 30% to about 70% of water to a temperature of about 115° C. to about 128° C. for about 15 minutes to about 60 minutes under nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.Type: GrantFiled: March 4, 2021Date of Patent: July 12, 2022Assignee: Somerset Therapeutics LLCInventors: Rahul Kalhapure, Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Publication number: 20220110891Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.Type: ApplicationFiled: November 15, 2021Publication date: April 14, 2022Applicant: Nevakar Injectables Inc.Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
-
Patent number: 11207280Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.Type: GrantFiled: March 17, 2020Date of Patent: December 28, 2021Assignee: Nevakar Injectables Inc.Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
-
Publication number: 20210386699Abstract: The present invention relates to liquid formulations of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulations are devoid of tromethamine. In particular, the invention provides a stable ready-to-use liquid formulation of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulation is devoid of tromethamine. The formulations prepared by using the current invention exhibit good physical and chemical stability.Type: ApplicationFiled: June 14, 2021Publication date: December 16, 2021Applicant: Somerset Therapeutics LLCInventors: Prem Sagar Akasapu, Rahul Kalhapure, Mandar V. Shah, Shambhavi Borde, Veerappan Subramanian, Ilango Subramanian
-
Publication number: 20210275451Abstract: The present invention relates to a process for preparation of an insoluble corticosteroid and a soluble corticosteroid composition by moist heat sterilization and homogenization. In particular, the invention relates to a process for the preparation of a sterilized suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises sterilizing a slurry of the betamethasone acetate by moist heat sterilization or autoclaving in about 30% to about 70% of water to a temperature of about 115° C. to about 128° C. for about 15 minutes to about 60 minutes under nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.Type: ApplicationFiled: March 4, 2021Publication date: September 9, 2021Applicant: Somerset Therapeutics LLCInventors: Rahul Kalhapure, Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Publication number: 20210252019Abstract: The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. The invention particularly relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization or autoclaving of an aqueous slurry of methylprednisolone acetate in the presence of a specified quantity of polysorbate. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.Type: ApplicationFiled: February 14, 2020Publication date: August 19, 2021Applicant: Somerset Therapeutics LLCInventors: Rahul Kalhapure, Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Publication number: 20210251903Abstract: The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. Particularly, the invention relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization of an aqueous slurry of the steroid triamcinolone acetonide in the presence of benzyl alcohol, sodium chloride and sodium carboxymethylcellulose under a nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.Type: ApplicationFiled: February 14, 2020Publication date: August 19, 2021Applicant: Somerset Therapeutics LLCInventors: Rahul Kalhapure, Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Patent number: 11083698Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.Type: GrantFiled: March 17, 2020Date of Patent: August 10, 2021Assignee: NEVAKAR INC.Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
-
Patent number: 11071719Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.Type: GrantFiled: February 12, 2020Date of Patent: July 27, 2021Assignee: NEVAKAR INC.Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
-
Patent number: 11071732Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.Type: GrantFiled: February 20, 2019Date of Patent: July 27, 2021Assignee: NEVAKAR INC.Inventors: Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
-
Publication number: 20210212933Abstract: The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.Type: ApplicationFiled: January 13, 2021Publication date: July 15, 2021Applicant: Somerset Therapeutics LLCInventors: Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Publication number: 20210169897Abstract: Compositions and methods for injectable and liquid fulvestrant formulations that have fulvestrant at a relatively high concentration stably solubilized before and after injection of the patient are provided.Type: ApplicationFiled: December 6, 2018Publication date: June 10, 2021Inventors: Vivek Yadav, Sriramya Garapati, Bronislava Zektser, Varun Khurana, Iouri V Ilitchev, Prem Sagar Akasapu, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri